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213 Abstract
14 Therapeutic practices in equine reproductive medicine have dramatically evolved over the 
15 last 20 years but current usage is not described. The aims of this study were to provide a 
16 description of medication use and clinical findings of reproductive examinations alongside 
17 measures of reproductive efficiency in thoroughbreds.   A prospective cohort study was 
18 conducted in the 2013 and 2014 breeding seasons.  Mare and stallion details, information on 
19 veterinary interventions and findings of reproductive ultrasound scans were collected using 
20 questionnaires and entered into a custom-designed Microsoft Access database. Descriptive 
21 summary statistics were derived directly from the database and using Microsoft Excel.  
22 Information was collected from 2246 pregnancies in 1754 mares from 29 stud farms. 
23 Ovulatory induction agents were used in 91.8% of cases, oestrus induction agents in 38.4% 
24 and covering therapies in 62.7%. Intrauterine antimicrobials were used in 49.6% of mares.  
25 Single pregnancies accounted for 83.9% of pregnancies, twins for 15.3% and triplets for 
26 0.7%. The overall incidence of pregnancy loss between days 15-42 was 6.4% (95% CI 5.4%, 
27 7.4%) and 1.6% (95% CI 1.1%, 2.1%) between days 42-65. A further 1.37% of pregnancies 
28 were lost by October and 4.53% by birth (including stillbirths). Eighty-threesix percent of all 
29 pregnancies resulted in a live foal. In conclusion, there has been a considerable increase in 
30 the use of reproductive therapeutics over the last 12 years. Nonetheless, incidence of 
31 pregnancy loss and live foal percentages remain essentially unchanged. Risk factor studies 
32 are required to determine if the substantial increase in therapeutic usage is conferring 
33 positive benefits. 
34
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437 1. Introduction 
38 The economic repercussions of equine reproductive failure and costs involved in attempting 
39 to improve reproductive parameters are considerable (Bosh et al., 2009a). Additionally, 
40 increased veterinary requirements and repeated covers resulting from failure to conceive or 
41 early pregnancy loss (EPL) are associated with welfare and safety implications for both mares 
42 and stallions (Campbell and Sandøe, 2015).  Keeping abreast of changes in veterinary 
43 reproductive management to ensure the efficacy of interventions in relation to reproductive 
44 efficiency is paramount in identifying areas of strength and, equally, areas of weakness where 
45 research to assist the industry can be focused.
46     A 2002 study of reproductive parameters from the 1998 UK breeding season showed that  
47 27.8% of oestrous cycles were induced by exogenous hormones whilst ovulation was induced 
48 in 51% of cycles (n=1911) (Morris and Allen, 2002).  Overall, 12.2% of cycles received uterine 
49 treatments which included oxytocin, intrauterine antibiotics and saline lavage. By the 2002 
50 breeding season, the percentage of oestrous cycles induced had increased to 39.6% and the 
51 use of ovulatory induction agents to 59.1% (n=5005). Whilst the use of ovulatory agents 
52 significantly reduced the number of matings per pregnancy, they were found to have no 
53 effects on per cycle pregnancy rate itself (Allen et al., 2007). Uterine treatments were used in 
54 32.6% of cycles in flat racing mares. This was a substantial increase from 12.2% just 4 years 
55 previously. Despite these large increases in therapeutic interventions, the per cycle pregnancy 
56 rate showed only modest increases from 59.9% to 63.9% whilst the percentage of live foals  in 
57 flat racing mares was 82.7% in the 1998 season and 79.1% in the 2002 season (although this 
58 latter figure did not account for 3.7% of pregnancies in which the outcome was unknown).  
559     The largest area of reproductive wastage shown in studies worldwide is pregnancy loss in 
60 the embryonic period (Allen et al., 2007; Nath et al., 2010; Hanlon et al., 2012).  The most 
61 recently reported incidence of EPL in UK flat racing thoroughbreds was from the 2002 season 
62 and showed it to affect 7.2% of pregnancies (Allen et al., 2007). The definition of EPL in the 
63 mare varies between studies but it most typically refers to loss of pregnancy in the embryonic 
64 period between the day of diagnosis and gestation day 42.  Losses occurring during the period 
65 of conceptus attachment and microcotyledon establishment, commencing around day 40, 
66 have not been quantified. These are major physiological events of early pregnancy, critical for 
67 its success.
68     There have been no large scale evaluations of reproductive efficiency of thoroughbred 
69 mares in the UK for over a decade and the last study conducted on American thoroughbreds 
70 was from the 2004 breeding season (Allen et al., 2007; Bosh et al., 2009b). Additionally, data 
71 relating to medication usage and ultrasonographic findings in these studies were limited.  A 
72 more recent New Zealand study described efficiency over the 2008 and 2009 breeding seasons 
73 but provided no measure of therapeutic use or reproductive examination findings (Hanlon et 
74 al., 2012).  Reproductive management has evolved and anecdotal evidence suggests that the 
75 use of therapeutic interventions has increased.  An updated study to reflect the current 
76 practices used in reproductive medicine and any concurrent changes in measures of 
77 reproductive efficiency is, therefore, warranted. This paper aims to provide a detailed 
78 description of current therapeutic practices, clinical findings of reproductive examinations and 
79 measures of reproductive efficiency in the management of thoroughbreds in and around 
80 Newmarket, UK. 
81
682 2. Materials and Methods
83 2.1. Study design and period
84     A prospective cohort study was conducted recording details on the reproductive 
85 management and occurrence of pregnancy loss in thoroughbred broodmares located on stud 
86 farms under the care of two large equine veterinary practices based in Newmarket, UK. Data 
87 were collected over the 2013 and 2014 breeding seasons.
88
89 2.2. Sample size calculation 
90     Sample size calculations performed for a concurrent study investigating risk factors for EPL 
91 suggested data were needed from around 2000 pregnancies. For the purpose of this 
92 descriptive paper, this allows estimation of EPL incidence with a precision of 1-2%, assuming 
93 a true incidence of 7% and a 95% confidence level. 
94
95 2.3. Selection of studs and horses
96     A convenience sample of 29 stud farms located in Suffolk, Norfolk and Hertfordshire was 
97 recruited through the two collaborating veterinary practices.  Permission for the use of data 
98 was received from all studs and data made available for all mares on the farms.  The inclusion 
99 criterion for a mare to be entered into the study was a positive day 14 to 17 routine pregnancy 
100 scan. Data were only collected for mares with clinical findings recorded throughout the entire 
101 period of early pregnancy (days 15-65). 
102
103
104
7105 2.4. Data collection
106     At the time of the initial positive pregnancy scan between gestational days 14 to 17, a 
107 questionnaire (Supplementary Survey 1) was completed by the stud secretary, the attending 
108 veterinarian or an investigator (BR). The following information was recorded:  
109 Mare data: name, age, stud farm, attending veterinarian, breeding status at the start of each 
110 season (defined as maiden – never mated, foaling – foaled at the start of the breeding season, 
111 barren – mated without a pregnancy in the previous year, rested - parous mare deliberately 
112 not mated the previous year) and if the mare suffered an EPL in the previous season.
113 Stallion data: name, age and book size. 
114 Veterinary reproductive data: start of season foaling date (foaling mares only), administration 
115 date/duration/dose of pre-oestrus hormone treatments, ovulatory induction agents and post 
116 covering therapies, number of oestrous cycles covered before the positive pregnancy scan, 
117 covering date(s), ovulation detection date and number and location of ovulation(s), presence 
118 of uterine fluid or uterine abnormalities post covering. 
119 Pregnancy scan data: gestational day and date of scan (up to day 65), number, location and 
120 size of embryonic vesicles, uterine or conceptus abnormalities and treatments given 
121 (Supplementary Survey 2).
122 EPL was defined as loss up to gestation day 65 rather than the typical day 42 to 45 used in 
123 previous studies to ensure losses associated with conceptus attachment and early 
124 placentation were accounted for (Stout and Troedsson, 2015).
125 When available, additional reproductive data from day 65 to term were also recorded 
126 including the results of routine reproductive ultrasound scans carried out in October and the 
127 number of live births. Data on the pregnancy status after day 65 were not available for all 
128 pregnancies. In order to validate the accuracy of information provided and to complete 
8129 records if data were not available from the stud farm a number of additional sources of 
130 information were used by investigators: An investigator (BR) used the veterinary hospital 
131 databases, online data from the Racing Post database (www.racingpost.co.uk) and JBIS (Japan) 
132 (www.jbis.jp)  and sales records from Tattersalls (UK), Arqana (France), Equibase (USA) and 
133 Baden-Badener Auktionsgesellschaft (Germany), as well as studbook information provided 
134 through Weatherbys (UK) and Aga Khan (France).  to validate the accuracy of information 
135 provided and to complete records if data were not available from the stud farm. Complete 
136 data were not available for all pregnancies. 
137 Data collected were manually entered into a custom-designed Microsoft Access database. All 
138 stud, veterinarian, mare and stallion names were coded to ensure anonymity.  The codes were 
139 recorded on a separate password-protected Microsoft Access database only accessible by two 
140 key personnel in the study (BR and AdM).
141 2.5. Statistical analysis 
142    Descriptive information was derived directly from the database using custom-written Access 
143 queries and Microsoft Excel. Proportions are reported with binomial exact 95% confidence 
144 intervals (CI). Continuous data are summarised using the mean and standard deviation (SD) or 
145 median and interquartile range (IQR), depending on the data distribution, calculated in 
146 GraphPad Prism (GraphPad Software Inc, CA, USA).  Incidence of pregnancy loss was 
147 calculated as number of cases of pregnancy loss relative to number of pregnancies and 
148 expressed as a percentage with corresponding binomial exact 95% confidence intervals (CI). 
149 No comparative statistical analyses were carried out, given that mares could be represented 
150 more than once in the dataset and analysis accounting for non-independence of observations 
151 was deemed to be beyond the scope of this descriptive study. 
9152 3. Results
153 3.1. Study population
154      Data were collected from 2246 pregnancies in total; 1237 in 2013 and 1009 in 2014 (Table 
155 1). This information came from 1754 mares with 412 mares included in both 2013 and 2014. 
156 Data were collected on 78 second pregnancies where a mare had lost her initial pregnancy 
157 and on two third pregnancies where a mare had lost both her first and second pregnancy of 
158 the season.  Mare age ranged from 2 to 24 years with median age of 8 years (IQR 5-11).  A 
159 total of 416 pregnancies were from maiden mares, 1408 from foaling mares, 307 from barren 
160 mares and 114 from rested mares (Table 2). 
161   There were 86 stallions in the study with ages ranging from 3 to 23 years. Median age was 
162 10 years (IQR 7-14). The number of pregnancies represented by individual stallions ranged 
163 from 1 to 178 with a median of 8 (IQR 2-35).  The total stud book size of stallions ranged from 
164 1 to 273 coverings with a median value of 110 (IQR 92-131) coverings (including covers of 
165 mares not in study). 
166     The total number of pregnancies from each of the 29 stud farms ranged from 1 to 366 with 
167 a median of 60 pregnancies per stud (IQR 14-126) over the two-year study period. Data were 
168 provided by 13 veterinarians; 9 from one practice providing data from 12 studs and 4 from the 
169 second practice providing data from 17 studs. 
170
171 3.2. Covering and conceptions 
172     Days from foaling to successful cover ranged from 8 to 123 with a median of 33 days (IQR 
173 28-48). Only eight pregnancies were conceived within 10 days of foaling and 33 within 20 days. 
10
174 The majority of pregnancies (73.7%) were conceived on the first cycle covered, 20.3% were 
175 conceived on the second cycle, 4.4% on the third cycle and 1.1% conceived on the fourth or 
176 fifth cycle. The percentage of maiden and foaling mares with a pregnancy conceived on the 
177 first cycle covered was 75.4% in both groups (95% CI 71.0, 79.5, and 73.1, 77.6 respectively) 
178 compared to 69.8% (95% CI 64.5, 74.7) of barren mares and 64.3% (95% CI 55.1, 72.6) of rested 
179 mares.
180
181 3.3. Therapeutic use
182     The use of therapeutic agents in relation to mare age and status can be seen in Table 2 
183 whilst dose ranges are listed in Table 3. 
184      Agents used to stimulate oestrus included: cloprostenol (Estrumate, MSD Animal Health, 
185 Milton Keynes, UK) (29.4% of pregnancies), altrenogest (Regumate, MSD Animal Health) or 
186 progesterone (PRID® Delta, CEVA Animal Health Ltd, Amersham, UK) (7.2%), domperidone 
187 (Domperidone, Medreich PLC, Feltham, UK; Motilium, Zentiva UK, Guildford, UK ) (2.2%), 
188 sulpiride (Sulpiride, Wockhardt, Wrexham, UK; Dolmatil, Sanofi-aventis, Guildford, UK) (2.6%) 
189 and combined oestradiol and progesterone, (Hagyard Equine Medical Institute, Lexington, 
190 USA) (2.2%). At least one of these agents was given in 38.4% of cases (Table 1). 
191     Ovulation was induced in 91.8% of pregnancies (Table 1). Deslorelin (BioRelease 
192 Deslorelin®, Caledonian Holdings, Ascot Vale, Australia; Ovuplant®, Dechra Veterinary 
193 Products, Shrewsbury, UK) was used in 63.8% of pregnancies, human Chorionic 
194 Gonadotrophin (hCG) (Chorulon®, MSD Animal Health) in 27.6% of pregnancies and buserelin 
195 (Receptal®, MSD Animal Health) in 0.5%. Use of ovulatory induction agents was similar across 
196 mare age and status groups (Table 2). 
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197     Post covering therapies were used in 62.7% of pregnancies. Intrauterine antibiotics were 
198 administered in 49.6% of all pregnancies. These included: penicillin (Depocillin®, MSD Animal 
199 Health), neomycin and penicillin (Neopen®, MSD Animal Health), gentamycin (Genta Equine® 
200 10%, Dechra Veterinary Products, Shrewsbury, UK; Gentaject® 10%, Franklin Pharmaceuticals 
201 Ltd., Trim, Ireland), framycetin (Framomycin® 15%, Novartis, Camberley, UK) and ceftiofur 
202 (Excenel®, Zoetis, London, UK).   Other treatments included intrauterine lavage (23.5%), 
203 oxytocin (Oxytocin™, MSD Animal Health) or carbetocin (Reprocine®, Vetoquinol, 
204 Buckingham, UK) (50%) and dexamethasone (Colvasone®, Norbrook, Great Corby, UK; 
205 Dexaject®, Dopharma, Anglesey, UK; Dexadreson®, MSD Animal Health) (0.6%) (Table 4). 
206     In an attempt to help maintain the vesicle after the initial positive scan, 5.9% of pregnancies 
207 received altrenogest starting between gestation day 11 to 20 and continuing to day 65+, 0.9% 
208 received prednisolone (Prednidale® 25, Dechra Veterinary Products) starting from day 14 to 
209 18 and continuing to day 40 to 65+ and 0.6% received buserelin on day 10 or 11 of gestation.
210   Treatments were given at the time of reduction of a multiple pregnancy in 69.4% of cases. 
211 Flunixin (Cronyxin®, Bimeda, Anglesey, UK, Flunixin®, Norbrook) was the most commonly used 
212 drug used in 59.4% of reductions, sedation with domosedan (Domosedan®, Vetoquinol; 
213 Medesedan®, Chanella, Hungerford, UK) and butorphanol (Butador®, Chanelle; Torbugesic®, 
214 Zoetis) in 24.2% of cases and hyoscine (Buscopan®, Boehringer, Bracknell, UK) in 2.2% of cases 
215 (Table 5). 
216
217 3.4. Uterine clinical findings
218   No fluid was detected by post cover ultrasound scans (days 1 to 3 of gestation) in 62.3% of 
219 cases, >0 and ≤ 1 cm of fluid in 23.8% of cases, > 1 cm and ≤ 2 cm in 10.3% of cases  and > 2 
12
220 cm of fluid in 3.6% of cases.  The percentage of mares with > 1 cm of fluid increased with mare 
221 age from 8.9% in mares aged 2 to 4 years to 20.4% in mares older than 19 years. 
222     Uterine cysts were found in 17.9% of cases (Table 1). Their occurrence increased with 
223 increasing mare age and they were found in just 1.4% of maiden mares compared to 20 to 
224 25% of barren, foaled or rested mares (Table 2).
225     Endometrial swabs taken within 72 hours of detection of EPL were collected and analysed 
226 in 69.1% (123/178) of cases of EPL. The decision as to whether or not to take a swab was made 
227 at the discretion of the individual stud farms and veterinarians. Of these 123 swabs, 83.7% 
228 were negative for bacterial and fungal growth with a polymorphonucleur (PMN) count of zero. 
229 A low growth of beta or alpha haemolytic Streptococcus or Escherichia coli was found in 10.6% 
230 of cases although these findings were not deemed clinically significant by the reporting 
231 pathologist and not interpreted as a cause of loss. A moderate growth of beta haemolytic 
232 Streptococcus was found in 1.6% of cases and a moderate or profuse growth of Escherichia 
233 coli in 2.4% of cases with the pathologist reporting a presumptive diagnosis of endometritis. 
234 In one case a significant inflammatory response was found with a PMN count of 3+ in the 
235 absence of any detected bacterial or fungal growth. 
236
237 3.5. Multiple ovulations and pregnancies
238     A single ovulation was detected in 78.0% of pregnancies. Multiple ovulations were 
239 categorised as unilateral double or triple ovulations (all ovulations from the same ovary) or 
240 bilateral double or triple ovulations (at least one ovulation from each ovary). These were 
241 reported in 9.3% and 12.7% of cases respectively (Table 5).  
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242     A single pregnancy was detected in 83.9% of cases, twins in 15.3% and triplets in 0.7%. The 
243 lower incidence of multiple ovulations in foaling mares was also reflected in the lower 
244 incidence of multiple pregnancies seen in this group compared to maiden, barren and rested 
245 mares. The percentage of multiple pregnancies was 19.0% (95% CI 16.4, 21.6) in mares which 
246 received an oestrus induction agent compared to 14.2% (95% CI 12.4, 16.0) in untreated 
247 mares. The percentage of multiple pregnancies was 16.4% (95% CI 14.8, 18.0) in pregnancies 
248 which received an ovulatory induction agent and 12.8% (95% CI 8.0, 17.6) in pregnancies 
249 resulting from a natural ovulation. As described above, treatments were given at the time of 
250 reduction of a multiple pregnancy in 69.4% of cases. 
251
252 3.6. Incidence of pregnancy loss and live foals
253     The incidence of pregnancy loss is reported in Table 1. Total incidence of EPL between days 
254 15 to 65 was 7.9 % (95% CI 6.8%, 9.0%). Six of the 412 mares (1.5%, 95% CI 0.4%, 2.6%) that 
255 had pregnancies included in 2013 and 2014 suffered an EPL in both seasons whilst seven of 
256 1189 (0.5%, 95% CI 0.2, 0.8) mares suffered two losses in 2013 and four of 977 (0.4%, 95% CI 
257 0.1, 0.7) mares suffered two losses in 2014.  
258     The total incidence of loss between day 65 and October was 1.37% (95% CI 0.9, 2.01.1, 2.2) 
259 (3227/20081932) and 4.53% (95% CI 3.6, 5.53.3, 5.2) between October and foaling 
260 (917888/1953835) (including still born foals). The outcome of the pregnancy was not 
261 identified in 4.1% (95% CI 3.3, 5.0) of cases. The overall incidence of pregnancy loss was 13.0% 
262 (95% CI 11.6, 14.56) and the percentage of all pregnancies resulting in a live foal was 82.9% 
263 (95% CI 81.3, 84.5) (Table 1). The foaling outcome was known for 2043 cases and of these a 
264 live foal was produced in 86.0% of pregnancies (95% CI 84.5, 87.5) (Table 1). 
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265      Table 2 shows measures of reproductive efficiency according to mare age and status. The 
266 increase in loss between days 15 to 65 for specific mare ages is seen in Fig 1a. Pregnancies in 
267 mares which suffered a loss between days 15 to 65 the previous season resulted in a live foal 
268 in 76.5% of cases (95% CI 68.8, 84.3) compared to 87.5% in those which maintained their 
269 pregnancy past this period (95% CI 85.7, 89.3). Incidence of EPL in mares that conceived a 
270 singleton pregnancy or a twin pregnancy that was subsequently reduced to a singleton was 
271 7.9% (95% CI 6.7, 9.2) and 7.8% (95% CI 5.5, 11.2) respectively. Incidence of EPL for individual 
272 stallions covering >10 pregnancies ranged from 0.0% (95% CI 0.0%, 14.6%) to 27.3 % (95% CI 
273 0.1%, 53.6%).  Figure 1b shows the incidence of EPL in relation to stallion age. The median 
274 book size of stallions covering pregnancies which were lost was 112 (IQR 93-130) and for those 
275 covering pregnancies which were maintained was 110 (IQR 92-131).
276
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277 4. Discussion
278     This prospective cohort study provides a much needed update on the reproductive 
279 management of pregnant thoroughbred maress and their reproductive efficiency as it relates 
280 to pregnancy. The main period of pregnancy loss was confirmed again to occur between 
281 gestation days 15 to 42. Despite a significant increase in the use of therapeutic interventions 
282 in this population over the past 12 years (Table 6), the incidences of early pregnancy loss 
283 (7.9%) and percentages of live foals (836.0%) have remained similar. 
284     Stallion book sizes have increased substantially over the past 30 to 40 years with popular 
285 stallions now routinely covering 100 to 150 mares (Weatherbys, 2017) and this number 
286 doubling in the case of shuttle stallions (Walbornn et al., 2017). Veterinarians and stud farm 
287 managers are faced with the combined pressures of producing foals early to maximise their 
288 sales potential whilst minimising coverings per mare (Commer et al., 1991). It is, therefore, 
289 unsurprising that they are increasingly utilising treatment options which are believed to 
290 promote these outcomes (Allen et al., 1980; Mari et al., 2009). Whilst the percentage of 
291 pregnancies resulting from an induced oestrus has remained unchanged, there has been a 
292 sharp increase since 2002 in the number of cases treated with ovulatory induction agents from 
293 59.1% (Allen et al., 2007) to 91.8%. This increase can be justified due to their ability to 
294 significantly reduce the number of matings per pregnancy (Allen et al., 2007).  
295     The percentage of pregnant mares receiving post covering treatment has also increased 
296 markedly  since 2002, from 36.4%  (Allen et al., 2007) to 62%.  The widespread use of covering 
297 treatments was similarly documented in a population of Irish thoroughbreds (31% of all 
298 mares) (Lane et al., 2016) while oxytocin and intrauterine antibiotics were used 
299 prophylactically in all 1916 thoroughbreds mares studied in the Midlands area of the UK 
16
300 between 2002 and 2007 (Davies Morel et al., 2012). The known ability of uterine infections to 
301 result in conception failures and/or EPL is likely the driving factor in this usage, however, 
302 evidence suggests they are in fact an uncommon cause of pregnancy loss. Ricketts et al. 
303 showed cytological evidence of acute endometritis in only three of 80 cases of EPL (4%) 
304 (Ricketts, 2003), similar to the incidence of 5.7% in the current study.  Low volumes of 
305 intrauterine fluid post mating are not thought to adversely affect pregnancy but volumes 
306 exceeding 2 cm, as detected in 3.6% of pregnancies in this study, are associated with reduced 
307 conceptions (Brinsko SP, 2003).   Additionally, previous findings show that just 10 to 15% of 
308 thoroughbred broodmares develop persistent mating-induced endometritis (Zent and 
309 Troedsson, 1998). A controlled study by Pycock and Newcombe (Pycock and Newcombe, 
310 1996a) found that treatment of mares with both oxytocin and intrauterine antibiotics within 
311 72 hours of mating resulted in higher pregnancy rates than untreated controls. A separate 
312 study found that oxytocin use alone 4 to 8 hours post cover resulted in improved pregnancy 
313 rates in mares susceptible to breeding-induced endometritis (Rasch et al., 1996). 
314 Dexamethasone is also used post covering and can aid in improving pregnancy rates in 
315 problematic mares with known risk factors for pregnancy failure (Bucca et al., 2008). Although 
316 evidence exists to warrant the use of covering medications in certain cases, the prevalence of 
317 both post mating induced and acute endometritis does not seem to justify the high use of 
318 covering medications seen. In a time when prudent antibiotics usage is paramount and the 
319 need for evidence based medicine is increasingly being recognised, appropriate case selection 
320 must be encouraged.
321     The use of altrenogest to supplement endogenous progesterone production and, hence, 
322 assist in maintaining early pregnancies has long been a contentious issue (Allen, 2001; Canisso 
323 et al., 2013). With few other treatment options available its use is often cited in problematic 
17
324 mares or those in which a small-for-age vesicle is found on ultrasound examination. It was 
325 used relatively infrequently in this study with just 5.9% of pregnancies receiving altrenogest 
326 post cover. Two previous studies supported the use of the gonadotrophin releasing hormone 
327 buserelin at day 10 or 11 of pregnancy to reduce losses occurring before gestational day 30 
328 (Pycock and Newcombe, 1996b; Newcombe et al., 2001) and so it is interesting to note that 
329 this was only used in 0.6% of mares in this study. 
330     The increasing use of reproductive therapies not only results in increased costs and labour 
331 but ethical and welfare implications must also be considered. The widespread use of 
332 antibiotics in particular may not be justifiable in the current environment of judicial 
333 antimicrobial usage (Campbell and Sandøe, 2015). We must, therefore, ensure that any effects 
334 on pregnancy outcome, either positive or negative, are fully recognised. Pregnancy losses 
335 between days 15 to 42 have changed little in the UK over the last 12 years with an incidence 
336 of 7.2% in 2002 (Allen et al., 2007) and 6.4% in our present study, with overlapping confidence 
337 intervals. These incidences are within the range reported internationally (5.5% to 8.9%) (Bosh 
338 et al., 2009b; Nath et al., 2010; Hanlon et al., 2012). Similarly, losses from day 42 to October 
339 (3.6% in 2002) (Allen et al., 2007) and losses from October to foaling (4.5% in 2002 and 4.53% 
340 in 2013/14) were comparable. As conception data were not recorded in the present study, the 
341 effects the changes in therapeutic use may have in this regard cannot be commented upon. 
342 However, taking into account sampling variation it appears that the increased use of therapies 
343 has brought no tangible changes, either positive or negative, on incidence of pregnancy loss 
344 at any period in gestation or live foal percentages. 
345     The effects of mare age and status on reproductive efficiency have been documented 
346 (Hemberg et al., 2004; Allen et al., 2007; Bosh et al., 2009a). Descriptive data presented in this 
347 study align with the increase in pregnancy loss and decrease in live foal percentages reported 
18
348 in older mares (Allen et al., 2007; Hanlon et al., 2012; Lane et al., 2016). Also in agreement 
349 with previous studies, the majority of losses reported here occurred in the early embryonic 
350 period (Nath et al., 2010; Hanlon et al., 2012). However, unlike these previous studies, by 
351 investigating the early pregnancy period up to day 65 rather than the traditional 35 to 42 days, 
352 the importance of this extra three week window was shown, with 101.4% of all losses 
353 occurring in this period. This is perhaps unsurprising given the critical events relating to 
354 pregnancy maintenance which occur during this small time frame. The sameA greater 
355 percentage of losses occurred between days 43 to 65 as in the months between day 65 of 
356 gestation to October (1.6% and 1.37% respectively). 
357 Possible causes of pregnancy loss between days 15 and 65 can be classified as being: (i) 
358 inherent to the mare (e.g. endometrial disease and oocyte abnormalities), (ii) inherent to the 
359 embryo (e.g. genetics of the embryo, both spontaneously induced changes or inherited) or (iii) 
360 external influences that can impact on early development (e.g. therapeutics administered in 
361 the periconception period, nutrition and exposure to pathogens).  Consistent with other 
362 studies (Allen et al., 2009; Bosh et al., 2009), here we report a significantly higher incidence of 
363 EPL in older mares. It is possible that this increase in EPL in older mares arises due to gross 
364 chromosomal defects of the conceptus, as observed with increasing maternal age in human 
365 pregnancy (Grande et al., 2012). Limited knowledge exists on the frequency of genetic 
366 abnormalities in equine embryos (Rambags et al., 2005) but with new methods recently 
367 published to obtain and study failed equine conceptuses (Rose et al., 2016) progress should 
368 follow shortly. The contribution of aging stallions to EPL is not known but it is interesting to 
369 note that oxidative stress and its associated damage to the spermatozoal DNA are known to 
370 increase the incidence of EPL experienced with increasing age in men (Kleinhaus et al., 2006).
371
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372 Multiple ovulations were seen in 22.0% of pregnancies in this study. This is reflective of the 
373 22.3% of cycles resulting in a multiple ovulation in a cohort of thoroughbred mares followed 
374 in the UK  from 1996 to 1998 (Davies Morel and O’Sullivan, 2001). Overall, there was an 
375 apparent modest increase in the number of multiple pregnancies detected from 10.5% in 2002 
376 (Allen et al., 2007) to 16.1% in 2013/14. This was also slightly higher than the incidences of 
377 12.1% seen in a 2010 Australian study and 12.9% in a 2012 study from New Zealand (Nath et 
378 al., 2010; Hanlon et al., 2012) although it is possible this is a reflection of sampling variation. 
379 Whilst previous studies have shown the occurrence of multiple ovulations to increase as mare 
380 age increases (Marinone et al., 2015; Davies-Morel et al., 2008), this effect was not seen here 
381 for either multiple ovulations or multiple pregnancies.  There was, however, a lower incidence 
382 of multiple ovulation and pregnancy in foaling mares compared with maiden, rested or barren 
383 mares. This could be explained by the suppressive effects of lactation and the higher metabolic 
384 demands experienced in foaling mares when compared with other mare groups. Future 
385 studies using multivariable models are warranted to identify factors that modify the risk of 
386 conceiving a twin pregnancy and improve our understanding of changes in the incidence of 
387 twin pregnancy over the last decade.
388     Flunixin was used in 59.4% of cases of manual twin reduction as it is thought to inhibit 
389 endogenous prostaglandin release from the endometrium, so reducing the risk of losing the 
390 remaining conceptus (Darenius et al., 1989). A recent Kentucky study showed that mares 
391 treated with flunixin and progesterone following manual twin reduction had a higher live foal 
392 rate than untreated mares (Sheerin, 2010). However, this finding was based on univariable 
393 analysis only and thus it was not clear whether this benefit resulted from flunixin, 
394 progesterone or operator. Further studies are required to determine if this high level of 
395 flunixin usage is warranted.
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396   In conclusion, this study has established therapeutic practices currently used in a study 
397 population of intensively managed thoroughbred broodmares and provided up-to-date 
398 estimates of pregnancy loss in this population. The veterinary management of thoroughbred 
399 broodmares in the Newmarket area of the UK has changed substantially since 2002 with 
400 induced ovulations now accounting for over 90% of pregnancies. Additionally, covering 
401 therapies including oxytocin, intrauterine antibiotics and lavage, and dexamethasone are now 
402 used in the majority of mares post cover. This is despite, in some cases, an absence of clinical 
403 signs of intrauterine pathology raising questions as to the need for their use, especially when 
404 considering that incidence of loss and percentages of live births are still comparable with 
405 previously reported data. Pregnancy loss was again found to be highest in the early embryonic 
406 period, highlighting the critical importance of this short phase of gestation and, for the first 
407 time, highlighting the importance of day 65 pregnancy scans due to the high proportion of 
408 losses occurring between days 42 and 65. The incidence of pregnancy loss described here 
409 differed between some subgroups of mares but variables such as mare age, status, presence 
410 of cysts and uterine treatments are likely to be inter-related and further multivariable analysis, 
411 beyond the scope of this paper, will be conducted to quantify the independent effect of each 
412 of these variables on EPL and other outcomes of interest. Such analysis is also needed to assess 
413 the beneficial or detrimental effects of reproductive therapeutics in respect to pregnancy loss.  
414 The notable increase in therapeutic use, particularly with respect to antibiotics, needs to be 
415 further investigated to ensure clinicians are provided with reliable evidence to guide decisions 
416 on optimal reproductive management of thoroughbred mares. 
417
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419 Figure and Table Legends
420 TABLE 1: Measures of reproductive management and efficiency in a cohort of intensively managed 
421 thoroughbred mares around Newmarket, UK (2013 and 2014 breeding seasons).  
422
423 TABLE 2: Measures of reproductive management and efficiency by mare age and status in a cohort of 
424 intensively managed thoroughbred mares around Newmarket, UK (2013 and 2014 breeding seasons).  
425
426 TABLE 3: Doses and routes of administration of drugs used in the reproductive management of 
427 intensively managed thoroughbred mares around Newmarket, UK (2013 and 2014 breeding seasons). 
428
429 TABLE 4: Covering therapies used in a cohort of intensively managed thoroughbred mares around 
430 Newmarket, UK (2013 and 2014 breeding seasons).
431
432 TABLE 5: Treatments used at the time of manual reduction of multiple pregnancies and associated 
433 incidence of early pregnancy loss in a cohort of intensively managed thoroughbred mares around 
434 Newmarket, UK (2013 and 2014 breeding seasons).
435
436 TABLE 6: Comparison of use of therapeutic agents in a population of flat race Thoroughbred mares 
437 between 1998 and 2014. aMorris et al, 2002, bAllen et al, 2007
438 Fig 1: The incidence of EPL in a cohort of intensively managed thoroughbred mares around Newmarket, 
439 UK (2013 and 2014 breeding seasons) according to a) age of mare b) age of stallion (number above 
440 each column reflects number of stallions of that age).  
441
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213 Abstract
14 Therapeutic practices in equine reproductive medicine have dramatically evolved over the 
15 last 20 years but current usage is not described. The aims of this study were to provide a 
16 description of medication use and clinical findings of reproductive examinations alongside 
17 measures of reproductive efficiency in thoroughbreds.   A prospective cohort study was 
18 conducted in the 2013 and 2014 breeding seasons.  Mare and stallion details, information on 
19 veterinary interventions and findings of reproductive ultrasound scans were collected using 
20 questionnaires and entered into a custom-designed Microsoft Access database. Descriptive 
21 summary statistics were derived directly from the database and using Microsoft Excel.  
22 Information was collected from 2246 pregnancies in 1754 mares from 29 stud farms. 
23 Ovulatory induction agents were used in 91.8% of cases, oestrus induction agents in 38.4% 
24 and covering therapies in 62.7%. Intrauterine antimicrobials were used in 49.6% of mares.  
25 Single pregnancies accounted for 83.9% of pregnancies, twins for 15.3% and triplets for 
26 0.7%. The overall incidence of pregnancy loss between days 15-42 was 6.4% (95% CI 5.4%, 
27 7.4%) and 1.6% (95% CI 1.1%, 2.1%) between days 42-65. A further 1.3% of pregnancies were 
28 lost by October and 4.5% by birth (including stillbirths). Eighty-three percent of all 
29 pregnancies resulted in a live foal. In conclusion, there has been a considerable increase in 
30 the use of reproductive therapeutics over the last 12 years. Nonetheless, incidence of 
31 pregnancy loss and live foal percentages remain essentially unchanged. Risk factor studies 
32 are required to determine if the substantial increase in therapeutic usage is conferring 
33 positive benefits. 
34
335 Keywords: Reproductive efficiency; therapeutics; management; twin pregnancies; antimicrobials; 
36 pregnancy loss
437 1. Introduction 
38 The economic repercussions of equine reproductive failure and costs involved in attempting 
39 to improve reproductive parameters are considerable (Bosh et al., 2009a). Additionally, 
40 increased veterinary requirements and repeated covers resulting from failure to conceive or 
41 early pregnancy loss (EPL) are associated with welfare and safety implications for both mares 
42 and stallions (Campbell and Sandøe, 2015).  Keeping abreast of changes in veterinary 
43 reproductive management to ensure the efficacy of interventions in relation to reproductive 
44 efficiency is paramount in identifying areas of strength and, equally, areas of weakness where 
45 research to assist the industry can be focused.
46     A 2002 study of reproductive parameters from the 1998 UK breeding season showed that  
47 27.8% of oestrous cycles were induced by exogenous hormones whilst ovulation was induced 
48 in 51% of cycles (n=1911) (Morris and Allen, 2002).  Overall, 12.2% of cycles received uterine 
49 treatments which included oxytocin, intrauterine antibiotics and saline lavage. By the 2002 
50 breeding season, the percentage of oestrous cycles induced had increased to 39.6% and the 
51 use of ovulatory induction agents to 59.1% (n=5005). Whilst the use of ovulatory agents 
52 significantly reduced the number of matings per pregnancy, they were found to have no 
53 effects on per cycle pregnancy rate itself (Allen et al., 2007). Uterine treatments were used in 
54 32.6% of cycles in flat racing mares. This was a substantial increase from 12.2% just 4 years 
55 previously. Despite these large increases in therapeutic interventions, the per cycle pregnancy 
56 rate showed only modest increases from 59.9% to 63.9% whilst the percentage of live foals  in 
57 flat racing mares was 82.7% in the 1998 season and 79.1% in the 2002 season (although this 
58 latter figure did not account for 3.7% of pregnancies in which the outcome was unknown).  
559     The largest area of reproductive wastage shown in studies worldwide is pregnancy loss in 
60 the embryonic period (Allen et al., 2007; Nath et al., 2010; Hanlon et al., 2012).  The most 
61 recently reported incidence of EPL in UK flat racing thoroughbreds was from the 2002 season 
62 and showed it to affect 7.2% of pregnancies (Allen et al., 2007). The definition of EPL in the 
63 mare varies between studies but it most typically refers to loss of pregnancy in the embryonic 
64 period between the day of diagnosis and gestation day 42.  Losses occurring during the period 
65 of conceptus attachment and microcotyledon establishment, commencing around day 40, 
66 have not been quantified. These are major physiological events of early pregnancy, critical for 
67 its success.
68     There have been no large scale evaluations of reproductive efficiency of thoroughbred 
69 mares in the UK for over a decade and the last study conducted on American thoroughbreds 
70 was from the 2004 breeding season (Allen et al., 2007; Bosh et al., 2009b). Additionally, data 
71 relating to medication usage and ultrasonographic findings in these studies were limited.  A 
72 more recent New Zealand study described efficiency over the 2008 and 2009 breeding seasons 
73 but provided no measure of therapeutic use or reproductive examination findings (Hanlon et 
74 al., 2012).  Reproductive management has evolved and anecdotal evidence suggests that the 
75 use of therapeutic interventions has increased.  An updated study to reflect the current 
76 practices used in reproductive medicine and any concurrent changes in measures of 
77 reproductive efficiency is, therefore, warranted. This paper aims to provide a detailed 
78 description of current therapeutic practices, clinical findings of reproductive examinations and 
79 measures of reproductive efficiency in the management of thoroughbreds in and around 
80 Newmarket, UK. 
81
682 2. Materials and Methods
83 2.1. Study design and period
84     A prospective cohort study was conducted recording details on the reproductive 
85 management and occurrence of pregnancy loss in thoroughbred broodmares located on stud 
86 farms under the care of two large equine veterinary practices based in Newmarket, UK. Data 
87 were collected over the 2013 and 2014 breeding seasons.
88
89 2.2. Sample size calculation 
90     Sample size calculations performed for a concurrent study investigating risk factors for EPL 
91 suggested data were needed from around 2000 pregnancies. For the purpose of this 
92 descriptive paper, this allows estimation of EPL incidence with a precision of 1-2%, assuming 
93 a true incidence of 7% and a 95% confidence level. 
94
95 2.3. Selection of studs and horses
96     A convenience sample of 29 stud farms located in Suffolk, Norfolk and Hertfordshire was 
97 recruited through the two collaborating veterinary practices.  Permission for the use of data 
98 was received from all studs and data made available for all mares on the farms.  The inclusion 
99 criterion for a mare to be entered into the study was a positive day 14 to 17 routine pregnancy 
100 scan. Data were only collected for mares with clinical findings recorded throughout the entire 
101 period of early pregnancy (days 15-65). 
102
103
104
7105 2.4. Data collection
106     At the time of the initial positive pregnancy scan between gestational days 14 to 17, a 
107 questionnaire (Supplementary Survey 1) was completed by the stud secretary, the attending 
108 veterinarian or an investigator (BR). The following information was recorded:  
109 Mare data: name, age, stud farm, attending veterinarian, breeding status at the start of each 
110 season (defined as maiden – never mated, foaling – foaled at the start of the breeding season, 
111 barren – mated without a pregnancy in the previous year, rested - parous mare deliberately 
112 not mated the previous year) and if the mare suffered an EPL in the previous season.
113 Stallion data: name, age and book size. 
114 Veterinary reproductive data: start of season foaling date (foaling mares only), administration 
115 date/duration/dose of pre-oestrus hormone treatments, ovulatory induction agents and post 
116 covering therapies, number of oestrous cycles covered before the positive pregnancy scan, 
117 covering date(s), ovulation detection date and number and location of ovulation(s), presence 
118 of uterine fluid or uterine abnormalities post covering. 
119 Pregnancy scan data: gestational day and date of scan (up to day 65), number, location and 
120 size of embryonic vesicles, uterine or conceptus abnormalities and treatments given 
121 (Supplementary Survey 2).
122 EPL was defined as loss up to gestation day 65 rather than the typical day 42 to 45 used in 
123 previous studies to ensure losses associated with conceptus attachment and early 
124 placentation were accounted for (Stout and Troedsson, 2015).
125 When available, additional reproductive data from day 65 to term were also recorded 
126 including the results of routine reproductive ultrasound scans carried out in October and the 
127 number of live births. Data on the pregnancy status after day 65 were not available for all 
128 pregnancies. In order to validate the accuracy of information provided and to complete 
8129 records if data were not available from the stud farm a number of additional sources of 
130 information were used by investigators: eterinary hospital databases, online data from the 
131 Racing Post database (www.racingpost.co.uk) and JBIS (Japan) (www.jbis.jp)  and sales records 
132 from Tattersalls (UK), Arqana (France), Equibase (USA) and Baden-Badener 
133 Auktionsgesellschaft (Germany), as well as studbook information provided through 
134 Weatherbys (UK) and Aga Khan (France). 
135 Data collected were manually entered into a custom-designed Microsoft Access database. All 
136 stud, veterinarian, mare and stallion names were coded to ensure anonymity.  The codes were 
137 recorded on a separate password-protected Microsoft Access database only accessible by two 
138 key personnel in the study (BR and AdM).
139 2.5. Statistical analysis 
140    Descriptive information was derived directly from the database using custom-written Access 
141 queries and Microsoft Excel. Proportions are reported with binomial exact 95% confidence 
142 intervals (CI). Continuous data are summarised using the mean and standard deviation (SD) or 
143 median and interquartile range (IQR), depending on the data distribution, calculated in 
144 GraphPad Prism (GraphPad Software Inc, CA, USA).  Incidence of pregnancy loss was 
145 calculated as number of cases of pregnancy loss relative to number of pregnancies and 
146 expressed as a percentage with corresponding binomial exact 95% confidence intervals (CI). 
147 No comparative statistical analyses were carried out, given that mares could be represented 
148 more than once in the dataset and analysis accounting for non-independence of observations 
149 was deemed to be beyond the scope of this descriptive study. 
150
9151 3. Results
152 3.1. Study population
153      Data were collected from 2246 pregnancies in total; 1237 in 2013 and 1009 in 2014 (Table 
154 1). This information came from 1754 mares with 412 mares included in both 2013 and 2014. 
155 Data were collected on 78 second pregnancies where a mare had lost her initial pregnancy 
156 and on two third pregnancies where a mare had lost both her first and second pregnancy of 
157 the season.  Mare age ranged from 2 to 24 years with median age of 8 years (IQR 5-11).  A 
158 total of 416 pregnancies were from maiden mares, 1408 from foaling mares, 307 from barren 
159 mares and 114 from rested mares (Table 2). 
160   There were 86 stallions in the study with ages ranging from 3 to 23 years. Median age was 
161 10 years (IQR 7-14). The number of pregnancies represented by individual stallions ranged 
162 from 1 to 178 with a median of 8 (IQR 2-35).  The total stud book size of stallions ranged from 
163 1 to 273 coverings with a median value of 110 (IQR 92-131) coverings (including covers of 
164 mares not in study). 
165     The total number of pregnancies from each of the 29 stud farms ranged from 1 to 366 with 
166 a median of 60 pregnancies per stud (IQR 14-126) over the two-year study period. Data were 
167 provided by 13 veterinarians; 9 from one practice providing data from 12 studs and 4 from the 
168 second practice providing data from 17 studs. 
169
170 3.2. Covering and conceptions 
171     Days from foaling to successful cover ranged from 8 to 123 with a median of 33 days (IQR 
172 28-48). Only eight pregnancies were conceived within 10 days of foaling and 33 within 20 days. 
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173 The majority of pregnancies (73.7%) were conceived on the first cycle covered, 20.3% were 
174 conceived on the second cycle, 4.4% on the third cycle and 1.1% conceived on the fourth or 
175 fifth cycle. The percentage of maiden and foaling mares with a pregnancy conceived on the 
176 first cycle covered was 75.4% in both groups (95% CI 71.0, 79.5, and 73.1, 77.6 respectively) 
177 compared to 69.8% (95% CI 64.5, 74.7) of barren mares and 64.3% (95% CI 55.1, 72.6) of rested 
178 mares.
179
180 3.3. Therapeutic use
181     The use of therapeutic agents in relation to mare age and status can be seen in Table 2 
182 whilst dose ranges are listed in Table 3. 
183      Agents used to stimulate oestrus included: cloprostenol (Estrumate, MSD Animal Health, 
184 Milton Keynes, UK) (29.4% of pregnancies), altrenogest (Regumate, MSD Animal Health) or 
185 progesterone (PRID® Delta, CEVA Animal Health Ltd, Amersham, UK) (7.2%), domperidone 
186 (Domperidone, Medreich PLC, Feltham, UK; Motilium, Zentiva UK, Guildford, UK ) (2.2%), 
187 sulpiride (Sulpiride, Wockhardt, Wrexham, UK; Dolmatil, Sanofi-aventis, Guildford, UK) (2.6%) 
188 and combined oestradiol and progesterone, (Hagyard Equine Medical Institute, Lexington, 
189 USA) (2.2%). At least one of these agents was given in 38.4% of cases (Table 1). 
190     Ovulation was induced in 91.8% of pregnancies (Table 1). Deslorelin (BioRelease 
191 Deslorelin®, Caledonian Holdings, Ascot Vale, Australia; Ovuplant®, Dechra Veterinary 
192 Products, Shrewsbury, UK) was used in 63.8% of pregnancies, human Chorionic 
193 Gonadotrophin (hCG) (Chorulon®, MSD Animal Health) in 27.6% of pregnancies and buserelin 
194 (Receptal®, MSD Animal Health) in 0.5%. Use of ovulatory induction agents was similar across 
195 mare age and status groups (Table 2). 
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196     Post covering therapies were used in 62.7% of pregnancies. Intrauterine antibiotics were 
197 administered in 49.6% of all pregnancies. These included: penicillin (Depocillin®, MSD Animal 
198 Health), neomycin and penicillin (Neopen®, MSD Animal Health), gentamycin (Genta Equine® 
199 10%, Dechra Veterinary Products, Shrewsbury, UK; Gentaject® 10%, Franklin Pharmaceuticals 
200 Ltd., Trim, Ireland), framycetin (Framomycin® 15%, Novartis, Camberley, UK) and ceftiofur 
201 (Excenel®, Zoetis, London, UK).   Other treatments included intrauterine lavage (23.5%), 
202 oxytocin (Oxytocin™, MSD Animal Health) or carbetocin (Reprocine®, Vetoquinol, 
203 Buckingham, UK) (50%) and dexamethasone (Colvasone®, Norbrook, Great Corby, UK; 
204 Dexaject®, Dopharma, Anglesey, UK; Dexadreson®, MSD Animal Health) (0.6%) (Table 4). 
205     In an attempt to help maintain the vesicle after the initial positive scan, 5.9% of pregnancies 
206 received altrenogest starting between gestation day 11 to 20 and continuing to day 65+, 0.9% 
207 received prednisolone (Prednidale® 25, Dechra Veterinary Products) starting from day 14 to 
208 18 and continuing to day 40 to 65+ and 0.6% received buserelin on day 10 or 11 of gestation.
209   Treatments were given at the time of reduction of a multiple pregnancy in 69.4% of cases. 
210 Flunixin (Cronyxin®, Bimeda, Anglesey, UK, Flunixin®, Norbrook) was the most commonly used 
211 drug used in 59.4% of reductions, sedation with domosedan (Domosedan®, Vetoquinol; 
212 Medesedan®, Chanella, Hungerford, UK) and butorphanol (Butador®, Chanelle; Torbugesic®, 
213 Zoetis) in 24.2% of cases and hyoscine (Buscopan®, Boehringer, Bracknell, UK) in 2.2% of cases 
214 (Table 5). 
215
216 3.4. Uterine clinical findings
217   No fluid was detected by post cover ultrasound scans (days 1 to 3 of gestation) in 62.3% of 
218 cases, >0 and ≤ 1 cm of fluid in 23.8% of cases, > 1 cm and ≤ 2 cm in 10.3% of cases  and > 2 
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219 cm of fluid in 3.6% of cases.  The percentage of mares with > 1 cm of fluid increased with mare 
220 age from 8.9% in mares aged 2 to 4 years to 20.4% in mares older than 19 years. 
221     Uterine cysts were found in 17.9% of cases (Table 1). Their occurrence increased with 
222 increasing mare age and they were found in just 1.4% of maiden mares compared to 20 to 
223 25% of barren, foaled or rested mares (Table 2).
224     Endometrial swabs taken within 72 hours of detection of EPL were collected and analysed 
225 in 69.1% (123/178) of cases of EPL. The decision as to whether or not to take a swab was made 
226 at the discretion of the individual stud farms and veterinarians. Of these 123 swabs, 83.7% 
227 were negative for bacterial and fungal growth with a polymorphonucleur (PMN) count of zero. 
228 A low growth of beta or alpha haemolytic Streptococcus or Escherichia coli was found in 10.6% 
229 of cases although these findings were not deemed clinically significant by the reporting 
230 pathologist and not interpreted as a cause of loss. A moderate growth of beta haemolytic 
231 Streptococcus was found in 1.6% of cases and a moderate or profuse growth of Escherichia 
232 coli in 2.4% of cases with the pathologist reporting a presumptive diagnosis of endometritis. 
233 In one case a significant inflammatory response was found with a PMN count of 3+ in the 
234 absence of any detected bacterial or fungal growth. 
235
236 3.5. Multiple ovulations and pregnancies
237     A single ovulation was detected in 78.0% of pregnancies. Multiple ovulations were 
238 categorised as unilateral double or triple ovulations (all ovulations from the same ovary) or 
239 bilateral double or triple ovulations (at least one ovulation from each ovary). These were 
240 reported in 9.3% and 12.7% of cases respectively (Table 5).  
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241     A single pregnancy was detected in 83.9% of cases, twins in 15.3% and triplets in 0.7%. The 
242 lower incidence of multiple ovulations in foaling mares was also reflected in the lower 
243 incidence of multiple pregnancies seen in this group compared to maiden, barren and rested 
244 mares. The percentage of multiple pregnancies was 19.0% (95% CI 16.4, 21.6) in mares which 
245 received an oestrus induction agent compared to 14.2% (95% CI 12.4, 16.0) in untreated 
246 mares. The percentage of multiple pregnancies was 16.4% (95% CI 14.8, 18.0) in pregnancies 
247 which received an ovulatory induction agent and 12.8% (95% CI 8.0, 17.6) in pregnancies 
248 resulting from a natural ovulation. As described above, treatments were given at the time of 
249 reduction of a multiple pregnancy in 69.4% of cases. 
250
251 3.6. Incidence of pregnancy loss and live foals
252     The incidence of pregnancy loss is reported in Table 1. Total incidence of EPL between days 
253 15 to 65 was 7.9 % (95% CI 6.8%, 9.0%). Six of the 412 mares (1.5%, 95% CI 0.4%, 2.6%) that 
254 had pregnancies included in 2013 and 2014 suffered an EPL in both seasons whilst seven of 
255 1189 (0.5%, 95% CI 0.2, 0.8) mares suffered two losses in 2013 and four of 977 (0.4%, 95% CI 
256 0.1, 0.7) mares suffered two losses in 2014.  
257     The total incidence of loss between day 65 and October was 1.3% (95% CI 0.9, 2.0) (27/2008) 
258 and 4.5% (95% CI3.6, 5.5) between October and foaling (88/1953) (including still born foals). 
259 The outcome of the pregnancy was not identified in 4.1% (95% CI 3.3, 5.0) of cases. The overall 
260 incidence of pregnancy loss was 13.0% (95% CI 11.6, 14.5) and the percentage of all 
261 pregnancies resulting in a live foal was 82.9% (95% CI 81.3, 84.5) (Table 1). 
262      Table 2 shows measures of reproductive efficiency according to mare age and status. The 
263 increase in loss between days 15 to 65 for specific mare ages is seen in Fig 1a. Pregnancies in 
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264 mares which suffered a loss between days 15 to 65 the previous season resulted in a live foal 
265 in 76.5% of cases (95% CI 68.8, 84.3) compared to 87.5% in those which maintained their 
266 pregnancy past this period (95% CI 85.7, 89.3). Incidence of EPL in mares that conceived a 
267 singleton pregnancy or a twin pregnancy that was subsequently reduced to a singleton was 
268 7.9% (95% CI 6.7, 9.2) and 7.8% (95% CI 5.5, 11.2) respectively. Incidence of EPL for individual 
269 stallions covering >10 pregnancies ranged from 0.0% (95% CI 0.0%, 14.6%) to 27.3 % (95% CI 
270 0.1%, 53.6%).  Figure 1b shows the incidence of EPL in relation to stallion age. The median 
271 book size of stallions covering pregnancies which were lost was 112 (IQR 93-130) and for those 
272 covering pregnancies which were maintained was 110 (IQR 92-131).
273
15
274 4. Discussion
275     This prospective cohort study provides a much needed update on the reproductive 
276 management of pregnant thoroughbred mares and their reproductive efficiency as it relates 
277 to pregnancy. The main period of pregnancy loss was confirmed again to occur between 
278 gestation days 15 to 42. Despite a significant increase in the use of therapeutic interventions 
279 in this population over the past 12 years (Table 6), the incidences of early pregnancy loss 
280 (7.9%) and percentages of live foals (83.0%) have remained similar. 
281     Stallion book sizes have increased substantially over the past 30 to 40 years with popular 
282 stallions now routinely covering 100 to 150 mares (Weatherbys, 2017) and this number 
283 doubling in the case of shuttle stallions (Walbornn et al., 2017). Veterinarians and stud farm 
284 managers are faced with the combined pressures of producing foals early to maximise their 
285 sales potential whilst minimising coverings per mare (Commer et al., 1991). It is, therefore, 
286 unsurprising that they are increasingly utilising treatment options which are believed to 
287 promote these outcomes (Allen et al., 1980; Mari et al., 2009). Whilst the percentage of 
288 pregnancies resulting from an induced oestrus has remained unchanged, there has been a 
289 sharp increase since 2002 in the number of cases treated with ovulatory induction agents from 
290 59.1% (Allen et al., 2007) to 91.8%. This increase can be justified due to their ability to 
291 significantly reduce the number of matings per pregnancy (Allen et al., 2007).  
292     The percentage of pregnant mares receiving post covering treatment has also increased 
293 markedly  since 2002, from 36.4%  (Allen et al., 2007) to 62%.  The widespread use of covering 
294 treatments was similarly documented in a population of Irish thoroughbreds (31% of all 
295 mares) (Lane et al., 2016) while oxytocin and intrauterine antibiotics were used 
296 prophylactically in all 1916 thoroughbreds mares studied in the Midlands area of the UK 
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297 between 2002 and 2007 (Davies Morel et al., 2012). The known ability of uterine infections to 
298 result in conception failures and/or EPL is likely the driving factor in this usage, however, 
299 evidence suggests they are in fact an uncommon cause of pregnancy loss. Ricketts et al. 
300 showed cytological evidence of acute endometritis in only three of 80 cases of EPL (4%) 
301 (Ricketts, 2003), similar to the incidence of 5.7% in the current study.  Low volumes of 
302 intrauterine fluid post mating are not thought to adversely affect pregnancy but volumes 
303 exceeding 2 cm, as detected in 3.6% of pregnancies in this study, are associated with reduced 
304 conceptions (Brinsko, 2003).   Additionally, previous findings show that just 10 to 15% of 
305 thoroughbred broodmares develop persistent mating-induced endometritis (Zent and 
306 Troedsson, 1998). A controlled study by Pycock and Newcombe (Pycock and Newcombe, 
307 1996a) found that treatment of mares with both oxytocin and intrauterine antibiotics within 
308 72 hours of mating resulted in higher pregnancy rates than untreated controls. A separate 
309 study found that oxytocin use alone 4 to 8 hours post cover resulted in improved pregnancy 
310 rates in mares susceptible to breeding-induced endometritis (Rasch et al., 1996). 
311 Dexamethasone is also used post covering and can aid in improving pregnancy rates in 
312 problematic mares with known risk factors for pregnancy failure (Bucca et al., 2008). Although 
313 evidence exists to warrant the use of covering medications in certain cases, the prevalence of 
314 both post mating induced and acute endometritis does not seem to justify the high use of 
315 covering medications seen. In a time when prudent antibiotics usage is paramount and the 
316 need for evidence based medicine is increasingly being recognised, appropriate case selection 
317 must be encouraged.
318     The use of altrenogest to supplement endogenous progesterone production and, hence, 
319 assist in maintaining early pregnancies has long been a contentious issue (Allen, 2001; Canisso 
320 et al., 2013). With few other treatment options available its use is often cited in problematic 
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321 mares or those in which a small-for-age vesicle is found on ultrasound examination. It was 
322 used relatively infrequently in this study with just 5.9% of pregnancies receiving altrenogest 
323 post cover. Two previous studies supported the use of the gonadotrophin releasing hormone 
324 buserelin at day 10 or 11 of pregnancy to reduce losses occurring before gestational day 30 
325 (Pycock and Newcombe, 1996b; Newcombe et al., 2001) and so it is interesting to note that 
326 this was only used in 0.6% of mares in this study. 
327     The increasing use of reproductive therapies not only results in increased costs and labour 
328 but ethical and welfare implications must also be considered. The widespread use of 
329 antibiotics in particular may not be justifiable in the current environment of judicial 
330 antimicrobial usage (Campbell and Sandøe, 2015). We must, therefore, ensure that any effects 
331 on pregnancy outcome, either positive or negative, are fully recognised. Pregnancy losses 
332 between days 15 to 42 have changed little in the UK over the last 12 years with an incidence 
333 of 7.2% in 2002 (Allen et al., 2007) and 6.4% in our present study, with overlapping confidence 
334 intervals. These incidences are within the range reported internationally (5.5% to 8.9%) (Bosh 
335 et al., 2009b; Nath et al., 2010; Hanlon et al., 2012). Similarly, losses from day 42 to October 
336 (3.6% in 2002) (Allen et al., 2007) and losses from October to foaling (4.5% in 2002 and 4.5% 
337 in 2013/14) were comparable. As conception data were not recorded in the present study, the 
338 effects the changes in therapeutic use may have in this regard cannot be commented upon. 
339 However, taking into account sampling variation it appears that the increased use of therapies 
340 has brought no tangible changes, either positive or negative, on incidence of pregnancy loss 
341 at any period in gestation or live foal percentages. 
342     The effects of mare age and status on reproductive efficiency have been documented 
343 (Hemberg et al., 2004; Allen et al., 2007; Bosh et al., 2009a). Descriptive data presented in this 
344 study align with the increase in pregnancy loss and decrease in live foal percentages reported 
18
345 in older mares (Allen et al., 2007; Hanlon et al., 2012; Lane et al., 2016). Also in agreement 
346 with previous studies, the majority of losses reported here occurred in the early embryonic 
347 period (Nath et al., 2010; Hanlon et al., 2012). However, unlike these previous studies, by 
348 investigating the early pregnancy period up to day 65 rather than the traditional 35 to 42 days, 
349 the importance of this extra three week window was shown, with 10% of all losses occurring 
350 in this period. This is perhaps unsurprising given the critical events relating to pregnancy 
351 maintenance which occur during this small time frame. A greater percentage of losses 
352 occurred between days 43 to 65 as in the months between day 65 of gestation to October 
353 (1.6% and 1.3% respectively). 
354 Possible causes of pregnancy loss between days 15 and 65 can be classified as being: (i) 
355 inherent to the mare (e.g. endometrial disease and oocyte abnormalities), (ii) inherent to the 
356 embryo (e.g. genetics of the embryo, both spontaneously induced changes or inherited) or (iii) 
357 external influences that can impact on early development (e.g. therapeutics administered in 
358 the periconception period, nutrition and exposure to pathogens).  Consistent with other 
359 studies (Allen et al., 2009; Bosh et al., 2009), here we report a significantly higher incidence of 
360 EPL in older mares. It is possible that this increase in EPL in older mares arises due to gross 
361 chromosomal defects of the conceptus, as observed with increasing maternal age in human 
362 pregnancy (Grande et al., 2012). Limited knowledge exists on the frequency of genetic 
363 abnormalities in equine embryos (Rambags et al., 2005) but with new methods recently 
364 published to obtain and study failed equine conceptuses (Rose et al., 2016) progress should 
365 follow shortly. The contribution of aging stallions to EPL is not known but it is interesting to 
366 note that oxidative stress and its associated damage to the spermatozoal DNA are known to 
367 increase the incidence of EPL experienced with increasing age in men (Kleinhaus et al., 2006).
368
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369 Multiple ovulations were seen in 22.0% of pregnancies in this study. This is reflective of the 
370 22.3% of cycles resulting in a multiple ovulation in a cohort of thoroughbred mares followed 
371 in the UK  from 1996 to 1998 (Davies Morel and O’Sullivan, 2001). Overall, there was an 
372 apparent  increase in the number of multiple pregnancies detected from 10.5% in 2002 (Allen 
373 et al., 2007) to 16.1% in 2013/14. This was also slightly higher than the incidences of 12.1% 
374 seen in a 2010 Australian study and 12.9% in a 2012 study from New Zealand (Nath et al., 
375 2010; Hanlon et al., 2012) although it is possible this is a reflection of sampling variation. 
376 Whilst previous studies have shown the occurrence of multiple ovulations to increase as mare 
377 age increases (Marinone et al., 2015; Davies-Morel et al., 2008), this effect was not seen here 
378 for either multiple ovulations or multiple pregnancies.  There was, however, a lower incidence 
379 of multiple ovulation and pregnancy in foaling mares compared with maiden, rested or barren 
380 mares. This could be explained by the suppressive effects of lactation and the higher metabolic 
381 demands experienced in foaling mares when compared with other mare groups. Future 
382 studies using multivariable models are warranted to identify factors that modify the risk of 
383 conceiving a twin pregnancy and improve our understanding of changes in the incidence of 
384 twin pregnancy over the last decade.
385     Flunixin was used in 59.4% of cases of manual twin reduction as it is thought to inhibit 
386 endogenous prostaglandin release from the endometrium, so reducing the risk of losing the 
387 remaining conceptus (Darenius et al., 1989). A recent Kentucky study showed that mares 
388 treated with flunixin and progesterone following manual twin reduction had a higher live foal 
389 rate than untreated mares (Sheerin, 2010). However, this finding was based on univariable 
390 analysis only and thus it was not clear whether this benefit resulted from flunixin, 
391 progesterone or operator. Further studies are required to determine if this high level of 
392 flunixin usage is warranted.
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393   In conclusion, this study has established therapeutic practices currently used in a study 
394 population of intensively managed thoroughbred broodmares and provided up-to-date 
395 estimates of pregnancy loss in this population. The veterinary management of thoroughbred 
396 broodmares in the Newmarket area of the UK has changed substantially since 2002 with 
397 induced ovulations now accounting for over 90% of pregnancies. Additionally, covering 
398 therapies including oxytocin, intrauterine antibiotics and lavage, and dexamethasone are now 
399 used in the majority of mares post cover. This is despite, in some cases, an absence of clinical 
400 signs of intrauterine pathology raising questions as to the need for their use, especially when 
401 considering that incidence of loss and percentages of live births are still comparable with 
402 previously reported data. Pregnancy loss was again found to be highest in the early embryonic 
403 period, highlighting the critical importance of this short phase of gestation and, for the first 
404 time, highlighting the importance of day 65 pregnancy scans due to the high proportion of 
405 losses occurring between days 42 and 65. The incidence of pregnancy loss described here 
406 differed between some subgroups of mares but variables such as mare age, status, presence 
407 of cysts and uterine treatments are likely to be inter-related and further multivariable analysis, 
408 beyond the scope of this paper, will be conducted to quantify the independent effect of each 
409 of these variables on EPL and other outcomes of interest. Such analysis is also needed to assess 
410 the beneficial or detrimental effects of reproductive therapeutics in respect to pregnancy loss.  
411 The notable increase in therapeutic use, particularly with respect to antibiotics, needs to be 
412 further investigated to ensure clinicians are provided with reliable evidence to guide decisions 
413 on optimal reproductive management of thoroughbred mares. 
414
21
416 Figure and Table Legends
417 TABLE 1: Measures of reproductive management and efficiency in a cohort of intensively managed 
418 thoroughbred mares around Newmarket, UK (2013 and 2014 breeding seasons).  
419
420 TABLE 2: Measures of reproductive management and efficiency by mare age and status in a cohort of 
421 intensively managed thoroughbred mares around Newmarket, UK (2013 and 2014 breeding seasons).  
422
423 TABLE 3: Doses and routes of administration of drugs used in the reproductive management of 
424 intensively managed thoroughbred mares around Newmarket, UK (2013 and 2014 breeding seasons). 
425
426 TABLE 4: Covering therapies used in a cohort of intensively managed thoroughbred mares around 
427 Newmarket, UK (2013 and 2014 breeding seasons).
428
429 TABLE 5: Treatments used at the time of manual reduction of multiple pregnancies and associated 
430 incidence of early pregnancy loss in a cohort of intensively managed thoroughbred mares around 
431 Newmarket, UK (2013 and 2014 breeding seasons).
432
433 TABLE 6: Comparison of use of therapeutic agents in a population of flat race Thoroughbred mares 
434 between 1998 and 2014. aMorris et al, 2002, bAllen et al, 2007
435 Fig 1: The incidence of EPL in a cohort of intensively managed thoroughbred mares around Newmarket, 
436 UK (2013 and 2014 breeding seasons) according to a) age of mare b) age of stallion (number above 
437 each column reflects number of stallions of that age).  
438
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TABLE 1: Measures of reproductive management and efficiency in a cohort of intensively 
managed thoroughbred mares in Newmarket, UK (2013 and 2014 breeding seasons).
 
 
Numbers in brackets in columns 2-4 indicate 95% confidence intervals. 
 2013 2014 Total
No. mares 1189 977 1754
No. of pregnancies 1237 1009 2246
% pregnancies with oestrus 
induced (n=2246)
39.9      
 (37.2, 42.7)
36.6    
  (33.6, 39.5)
38.4   
 (36.4, 40.4)
% pregnancies with ovulation 
induced (n=2246)
93.2  
 (91.8, 94.6)
90.1     
 (88.2, 91.9)
91.8 
  (90.7, 92.9)
%  pregnancies receiving 
treatment at covering (n=2246)
58.5    
    (55.7, 61.2)
66.4      
 (63.5, 69.3)
62.0       
 (60.0, 64.0)
% pregnancies with uterine 
cysts (n=2246)
18.5       
    (16.3, 20.7)
17.1       
(14.8, 19.4)
17.9      
 (16.3, 19.5)
% ovulations multiple 
(n=2246)
22.1        
(19.8, 24.5)
21.9        
(19.3, 24.5)
22.0        
(20.3, 23.8)
% pregnancies multiple
(n=2246)
15.5       
 (13.5, 17.5)
16.7        
(14.5, 19.1)
16.1       
 (14.5, 17.6)
% multiple pregnancies 
receiving treatment at 
reduction (n=360
69.1       
 (62.6, 75.7)
69.8        
 (62.9, 76.7)
69.4         
(64.6, 74.2)
% pregnancies lost day 15-42
(n=2246)
6.7
(5.5,8.3)
6.1
(4.8, 7.8)
6.4
(5.4,7.4)
% pregnancies lost day 43-65
(n=2097)
2.2
(1.4, 3.1)
1.0
(0.4, 1.6)
1.6
(1.1, 2.1)
% pregnancies lost day 65- 
October (n=1932)2008)
2.1          1.9
(1.2, 2.9)
 (1.3, 3.0)
1.1          0.7
(0.2, 1.4)
 (0.4, 1.7)
1.7          1.3
(0.9, 2.0)
 (1.1, 2.2)
% pregnancies lost October – 
foaling (n=1953833)
4.7
(3.5 6.1)4.0           
(2.8, 5.2)
4.3
(3.1, 5.9)4.6          
 (3.2, 6.0)
4.5
(3.6, 5.5)4.3               
(3.3, 5.2)
% all pregnancies resulting in 
live foal (n=18352246)
82.2
(80.0, 84.3) 
85.0        
(82.9, 87.0)
83.7
(81.3, 86.0)
87.3        
(85.1, 89.5)
82.9
(81.3,84.4)
86.0       
 (84.5, 87.5)
% all pregnancies with no 
outcome (n=2246)
3.4
(2.5, 4.6)
5.0
(3.7, 6.5)
4.1
(3.3, 5.0)
% all pregnancies lost (n=2246) 14.4(12.5, 16.5)
11.3
(9.4, 13.4)
13.0
(11.6, 14.5)
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22.0        
(20.3, 23.8)
% pregnancies multiple
(n=2246)
15.5       
 (13.5, 17.5)
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(0.4, 1.6)
1.6
(1.1, 2.1)
% pregnancies lost day 65- 
October (n=2008)
1.9
(1.2, 2.9)
0.7
(0.2, 1.4)
1.3
(0.9, 2.0)
% pregnancies lost October – 
foaling (n=1953)
4.7
(3.5 6.1)
4.3
(3.1, 5.9)
4.5
(3.6, 5.5)      
% all pregnancies resulting in 
live foal (n=2246)
82.2
(80.0, 84.3) 
83.7
(81.3, 86.0)
82.9
(81.3,84.4)
% all pregnancies with no 
outcome (n=2246)
3.4
(2.5, 4.6)
5.0
(3.7, 6.5)
4.1
(3.3, 5.0)
% all pregnancies lost (n=2246) 14.4(12.5, 16.5)
11.3
(9.4, 13.4)
13.0
(11.6, 14.5)
TABLE 2: Measures of reproductive management and efficiency by mare age and mare status in a cohort of intensively managed thoroughbred mares 
around Newmarket, UK (2013 and 2014 breeding seasons).  
The numbers in brackets in columns 2-9  indicate 95% confidence intervals.
Mare age (years) Mare status at start of breeding season
 2-4 5-10 11-19 >19 MAIDEN BARREN FOALING RESTED
No. mares 303 1213 619 25 408 286 1119 111
No. of pregnancies 309 1243 661 27 416 307 1408 114
% pregnancies with oestrus 
induced (n=2246)
45                                                           
(39.5, 50.6)
36.9
(34.2, 39.6)
37.7      
(34.0, 41.4)
51.9      
 (33.1, 70.8)
43.8       
(39.0, 48.0)
42.2             
(36.7, 47.7)
36.5             
(34.0, 39.0)
33.3            
(24.7, 42.0)
% pregnancies with ovulation 
induced (n=2246)
93.9                                 
(91.2, 96.6)
91.9        
(90.4, 93.4)
90          
(87.7, 92.3)
88.9        
(77.1, 100.0)
94.2            
(92, 96.5)
92.5          
(89.6, 95.5)
91.1          
(89.6, 92.6)
89.5          
(83.8, 95.1)
%  pregnancies receiving 
treatment at covering (n=2246)
49.5                                 
(43.9, 55.1)
58.3         
(55.6, 61.0)
76.1      
(72.9, 79.4)
88.9        
(77.1, 100.0)
49.5          
(44.7, 54.3)
67.9         
(61.5, 74.2)
64.3          
(61.8, 66.8)
64.0          
(55.2, 72.9)
% pregnancies with uterine cysts 
(n=2246)
1.6                                
(0.2, 3.0)
6.5         
(5.0, 7.9)
45.8      
(42.0, 49.6)
44.4         
(25.7, 63.1)
1.4           
(0.3, 2.5)
24.4       
(19.6, 29.2)
20.9        
 (18.8, 23.0)
23.0          
(15.3, 30.7)
% ovulations multiple 
(n=2246)
23.6                             
(18.9, 28.3)
20.4        
(18.2, 22.6)
23.5           
(20.3, 26.7)
22.2          
(6.5, 37.9)
26.9         
(22.6, 31.2)
31.8         
(26.6, 37.0)
18.2          
(16.2, 20.3)
24.8       
(16.7, 32.9)
% pregnancies multiple
(n=2246)
20.4                            
(15.9, 24.9)
14.1       
(12.2, 16.0)
17.1        
(14.2, 20.0)
22.2          
(6.5, 37.9)
21.7         
(17.7, 25.7)
23.1          
(18.4, 27.8)
12.6           
(10.9, 14.3)
19.5          
(12.2, 26.8)
% multiple pregnancies receiving 
treatment at reduction (n=360)
84.1                     
(75.1, 93.1)
70.9      
(64.2, 77.6)
65.5          
(56.7, 74.3)
50            
(10.0, 90.0)
77.78        
(69.2, 86.4)
66.2       
  (55.2, 77.2)
67.2           
(60.3, 74.1)
63.6         
(43.5, 83.7)
% pregnancies lost day 15-42 
(n=2240 (age) n=2245 (status)6)
1.9                          
(0.4, 3.4)
4.8        
 (3.6, 6.0)
11.0           
(8.6, 13.4)
14.818.5
    (1.46.3, 
28.238.1)
2.4            
(0.9, 3.9)
8.1        
(5.1,11.2)
7.1          
(5.8,8.4)
7.9         
   (2.9, 12.8)
% pregnancies lost day 43-65 
(n=2097)
0.7                            
(0, 1.6)
1.1           
(0.5, 1.7)
2.9          
(1.5, 4.3)
8.79.1
   (0.01.1, 
20.229.2)
0.7             
(0, 1.6)
3.2      
   (1.1, 5.2)
1.7            
(1.0, 2.4) 0
% pregnancies lost day 65- 
October (n=19322008)
1.51.4                         
(0.40, 3.52.9)
1.11.0          
(0.55, 1.77)  
2.22.8                    
(1.14, 4.23.8)
5.0            0.0
(0.0, 14.6)
1.89        
(0.75, 3.84)
1.6           1.5
(0.41, 3.82)
1.6           2           
 (0.79,  1.92.3)
1.01            
   (0, 3.2)
% pregnancies lost October – 
foaling (n=18331953)
1.52.2                         
(0.80, 4.73.1)
3.2            4.4
 (2.13.2, 
5.74.3)
5.2          5.8
(3.34.0, 7.28.1)
11.8          11.1
(0.01.4, 
27.134.7)
1.8            2.5
(0.41.1, 3.24.6)
6.1            5.9
(3.30, 9.61)
4.9              5.2
(3.7, 6.14.0, 
6.5)
3.2               
(0, 7.2(0.7, 9.0)
% all pregnancies resulting in live 
foal (n=2240 (age), n=2245 (status) 
(n=1835)
94.187.7                      
(83.592.1, 
916.1)
86.18.4       
(84.07.1, 
88.09.7)
7875.43       
(76.071.9, 
80.678.6)
62.559.3           
(48.438.8, 
76.777.6)
92.7    85.8
    (90.082.1, 
95.489.0)
80.7     77.6
   (76.072.5, 
85.482.1)
84.9      83.5
   (81.43.0, 
85.46.8)
82.5      79.8
  (75.2, 
89.971.3, 86.8)
TABLE 2: Measures of reproductive management and efficiency by mare age and mare status in a cohort of intensively managed thoroughbred mares 
around Newmarket, UK (2013 and 2014 breeding seasons).  
The numbers in brackets in columns 2-9  indicate 95% confidence intervals.
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 2-4 5-10 11-19 >19 MAIDEN BARREN FOALING RESTED
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(43.9, 55.1)
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(55.6, 61.0)
76.1      
(72.9, 79.4)
88.9        
(77.1, 100.0)
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(44.7, 54.3)
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(61.8, 66.8)
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(55.2, 72.9)
% pregnancies with uterine cysts 
(n=2246)
1.6                                
(0.2, 3.0)
6.5         
(5.0, 7.9)
45.8      
(42.0, 49.6)
44.4         
(25.7, 63.1)
1.4           
(0.3, 2.5)
24.4       
(19.6, 29.2)
20.9        
 (18.8, 23.0)
23.0          
(15.3, 30.7)
% ovulations multiple 
(n=2246)
23.6                             
(18.9, 28.3)
20.4        
(18.2, 22.6)
23.5           
(20.3, 26.7)
22.2          
(6.5, 37.9)
26.9         
(22.6, 31.2)
31.8         
(26.6, 37.0)
18.2          
(16.2, 20.3)
24.8       
(16.7, 32.9)
% pregnancies multiple
(n=2246)
20.4                            
(15.9, 24.9)
14.1       
(12.2, 16.0)
17.1        
(14.2, 20.0)
22.2          
(6.5, 37.9)
21.7         
(17.7, 25.7)
23.1          
(18.4, 27.8)
12.6           
(10.9, 14.3)
19.5          
(12.2, 26.8)
% multiple pregnancies receiving 
treatment at reduction (n=360)
84.1                     
(75.1, 93.1)
70.9      
(64.2, 77.6)
65.5          
(56.7, 74.3)
50            
(10.0, 90.0)
77.78        
(69.2, 86.4)
66.2       
  (55.2, 77.2)
67.2           
(60.3, 74.1)
63.6         
(43.5, 83.7)
% pregnancies lost day 15-42 
(n=2240 (age), n=2245 (status))
1.9                          
(0.4, 3.4)
4.8        
 (3.6, 6.0)
11.0           
(8.6, 13.4)
18.5
    (6.3, 38.1)
2.4            
(0.9, 3.9)
8.1        
(5.1,11.2)
7.1          
(5.8,8.4)
7.9         
   (2.9, 12.8)
% pregnancies lost day 43-65 
(n=2097)
0.7                            
(0, 1.6)
1.1           
(0.5, 1.7)
2.9          
(1.5, 4.3)
9.1
   (1.1, 29.2)
0.7             
(0, 1.6)
3.2      
   (1.1, 5.2)
1.7            
(1.0, 2.4) 0
% pregnancies lost day 65- October 
(n=2008)
1.4                         
(0.4, 3.5)
1.0          
(0.5, 1.7)  
2.2          
(1.1, 3.8)
0.0
(0.0)
1.8        
(0.7, 3.8)
1.5
(0.4, 3.8)
1.2           
 (0.7,  1.9)
1.0            
   (0, 3.2)
% pregnancies lost October – foaling 
(n=1953)
2.2                         
(0.8, 4.7)
4.4
 (3.2, 5.7)
5.8
(4.0, 8.1)
11.1
1.4, 34.7)
2.5
(1.1, 4.6)
5.9
(3.3, 9.6)
5.2
(4.0, 6.5)
3.2               
(0.7, 9.0)
% all pregnancies resulting in live foal 
(n=2240 (age), n=2245 (status)) 
87.7                      
(83.5, 91.1)
86.1       
(84.0, 88.0)
75.4       
(71.9, 78.6)
59.3           
(38.8, 77.6)
85.8
    (82.1, 89.0)
77.6
   (72.5, 82.1)
83.5
   (81.4, 85.4)
79.8
  (71.3, 86.8)
TABLE 3: Doses and route of administration of therapeutics used in the reproductive 
management of intensively managed thoroughbred mares in Newmarket, UK
IU=intrauterine, SC=subcutaneous, IV=intravenous, IM=intramuscular, SID= once per day, BID= twice 
per day
Drug Dose range Route of administration
Altrenogest 2.2 mg/ml 22-26.4 mg / horse Oral
Benzylpenicillin 300 mg/ml 3000-9000 mg /horse IU
Buserelin acetate 0.004 mg/ml 0.04 mg/horse SC
Butorphanol 10 mg/ml 3-10 mg/horse IV
N-butylscopolammonium 20 mg/ml 150 mg/horse IV
Carbetocin 0.07 mg/ml 0.175-0.245 mg/horse IM
Ceftiofur 50 mg/ml 1 g / horse IU
Cloprostenol 250 µg/mL 125- 500 µg/horse IM
Deslorelin 2.1 mg implant 2.1 mg/horse SC implant
Detomidine 10 mg/ml 3-10 mg/horse IV
Domperidone 10 mg tablets 500 mg sid or bid/horse Oral
Flunixin 50 mg/ml 50 mg/45 kg IV
Framycetin 150 mg/ml 1050-1500 mg/horse IU
Gentamycin 100 mg/ml 800 mg/horse IU
human Chorionic Gonadotrophin 
1500 iu
1500-3000 iu / horse IM 
Neomycin 100 mg/ml / penicillin 200 
mg/ml
2000 – 3000 mg neomycin / 4000-6000 mg 
penicillin / horse 
IU
Oxytocin 10 iu/ml 10-40 iu /horse IV / IM
Progesterone 50 mg/ml  / oestradiol 
17ß 3.33mg/ml
Progesterone 150 mg / oestradiol 17ß 9.99 mg 
/ horse
IM 
Progesterone releasing intravaginal 
device 1.55 g
1.55 g/horse Intravaginal implant
Sulpiride 400 mg tablets 400-800 mg sid or bid/horse Oral
TABLE 4: Covering therapies used in a cohort of intensively managed thoroughbred
 mares around Newmarket, UK (2013 and 2014 breeding seasons).
Intrauterine
antibiotics
Uterine 
lavage
Oxytocin/
carbetocin Dexamethasone
Number of
pregnancies
% of all 
pregnancies
x x 478 21.3
x 267 11.9
x x x 238 10.6
x x 196 8.7
x 79 3.5
x x x x 67 3.0
x x x 51 2.3
x x 12 0.5
x 7 0.3
x x 5 0.2
x x x 4 0.2
x x x 2 <0.1
x x 1 <0.1
x x 1 <0.1
x 1 <0.1
TABLE 5: Incidence of multiple ovulations/pregnancies, the location of embryos at the time 
of manual reduction and treatment of multiple pregnancies at time of reduction in a cohort of 
intensively managed thoroughbred mares around Newmarket, UK (2013 and 2014 breeding 
seasons).
Ovulations and multiple 
pregnancies Number of pregnancies % of all pregnancies
Multiple ovulations 488 22.0                             (18.3, 25.7)
Single ovulations 1728 78.0                      (76.3, 79.7)
Multiple pregnancies 360 16.1                    (15.2, 18.2)
Single pregnancies 1882 83.9                   (82.4, 85.4)
Pregnancies conceived 
from bilateral ovulation 281
12.7                    
             (11.3, 14.1)
Pregnancies conceived 
from double ovulation in 
same ovary
207 9.3           (8.1, 10.5)
Conceptuses in same 
location at time of 
reduction
99 4.4                                      (3.6, 5.3)
Conceptuses in different 
location at time of 
reduction
169 7.5                             (6.4, 8.6)
Treatment at multiple 
pregnancy reduction Number of multiple pregnancies % of multiple pregnancies
Flunixin only                           162                 45.0
Sedation only1 28                  7.8
Hyoscine only 1                  <0.1
Flunixin and sedation1 52                  14.4
Sedation1 and hyoscine 7 1.9
1 Sedation consisting of a combination of detomidine and butorphanol
TABLE 6: Comparison of use of therapeutic agents in a population of flat race 
Thoroughbred mares between 1998 and 2014. aMorris et al, 2002 (n=1144 mares), bAllen et 
al, 2007 (n=2321 mares), cThis study (n=1754 mares), ddata only available for combined Flat 
racing/National Hunt Thoroughbreds (n=3373 mares), na=same therapies utilised but 
breakdown not available
1998a 2002b 2013/14c
Therapeutic
% % %
Oestrous Induction 28 40 38
Ovulation Induction 51 59 92
Covering therapies
 Intrauterine antimicrobials
 Oxytocin/carbetocin
 Intrauterine lavage
12
na
na
na
33
25d
28d
10d
63
50
50
24
